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One of the primary objectives of any medical imaging proce-
dure is to provide accurate and, if possible, quantitative
information to aid the diagnosis and treatment of disease. In
oncology X-ray CT, Ultrasound and most recently Magnetic
Resonance Imaging all provide high resolution morpholog-
ical information. Conventional radioisotope imaging whilst
providing unique functional information is generally limited
by poor spatial resolution and sensitivity. If the development
of tissue malignancy can be detected in its early stages
through biochemical processes and if the effects of treatment
are best seen by changes in these processes then a high
resolution, quantitative, functional imaging technique is
required. The only technique satisfying these criteria is Posi-
tron Emission Tomography (PET).
PET is a technique for imaging non-invasively the in vivo
distribution of pharmaceuticals, labelled with positron emitt-
ing radionuclides, administered to humans. PET images can
provide information relating to the use of a radiopharma-
ceutical (RP) by the body tissues. These RP's range from
agents which localise in particular organs or tissues to those
which enable cellular processes to be measured, by labelling
DNA/RNA for instance. Such studies can determine the
rates of metabolism of glucose, oxygen and amino acids and
can also provide information relating to rates of protein
synthesis or cell proliferation. Importantly the sensitivity of
the technique allows nmol and pmol levels of the tracer to be
used minimising the chance of perturbing the system being
examined. PET is therefore almost unique in determining
quantitatively from images the function of body processes
not available from morphological techniques.
Applications ofPET to oncology
The majority of the current studies in PET are in neurQlogy
and cardiology, as detailed in Phelps et al. (1986). However
the high spatial resolution (-5 mm) and sensitivity to a
range of unique physiological agents is ideally suited to
applications in oncology where quantitative measurements of
biochemical processes should be of great value. The avail-
ability of C", N'3, 01' and F'8 from a compact cyclotron
offers the possibility of studying the basic physiology of
human cancer and allows laboratory and in vitro methods to
be extended to patients non-invasively. Access to F"8 allows
such studies to be extended off-sfte from the cyclotron pro-
viding a means of measuring tissue glucose metabolism, per-
fusion, amino acid uptake, receptor ligand mechanisms and
drug kinetics. Additionally longer lived nuclides (I'24, Ga66,
Co55) and those produced from in-house generators (Ga68,
Rb82, Cu62) provide an additional useful range of labels for
physiological probes.
PET studies can be divided into the general areas of
tumour perfusion and metabolism, cellular proliferation,
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anti-cancer drug kinetics, receptor mechanisms and tumour
targeting. In some cases the information provided by these
studies is already being used directly in the clinic to provide
valuable guidance in the management of cancer patients and
it is likely that this will increase steadily in future.
Perfusion, metabolism andpermeability measurements
A wide variation in tumour perfusion has been reported by
Beaney et al. (1985, 1987). These data indicate that even in
cases where there is a plentiful supply of blood and, hence,
oxygen, the tumour often has only a modest demand for this
supply. It has also been demonstrated by Patronas et al.
(1982) and Brooks et al. (1986) that the metabolism of
glucose takes place preferentially over oxygen in many
tumours.
F'8-fluorodeoxyglucose (FDG) is the most widely used of
PET tracers in oncology. The recent Society of Nuclear
Medicine AGM (SNM, 1990) reported the applications of
FDG imaging to primary cerebral tumours, breast cancer,
musculoskeletal cancer, lung cancer, prostate cancer,
melanoma and lymphoma. These studies illustrate the
attempts to determine the role of glucose metabolism in
tumour growth. As an example Valk et al. (1988) have shown
a significant difference in the metabolism of glucose in
primary cerebral tumours which have been successfully
treated and are mostly necrotic in comparison to those which
continue to grow apparently unabated. Similar results have
been obtained by Haberkorn et al. (1990) monitoring radio-
therapy of colonic carcinoma. Here patients responding to
treatment show a marked reduction in glucose metabolism in
metastases. The same group have shown (Knopp et al., 1990)
reductions in glucose metabolism of lung tumours responding
to radio- or chemotherapy. Alavi et al. (1988) have measured
a strong correlation between initial glucose metabolism and
prognosis for patients with primary cerebral tumours, the
result appearing stronger than that predicted by a simple
histological grading system.
Amino acid metabolism measurements in glioma also show
potential useful results. The high contrast achieved in images
due to the low amino acid demand of normal brain has
enabled Erikson et al. (1987) to show more accurately the
growing edge ofcerebral tumours using PET images of C"-1-
Methionine (CMT). It may be that the metabolism of essen-
tial amino acids can give a signal related to protein synthesis
rates in tumours, making these measurements a sensitive
marker of the early effects of therapy at the cellular level. An
example of the use of CMT is shown in Bergstrom et al.
(1987) where the response of prolactinomas to bromocriptine
is shown within hours of the start of treatment.
The effects of blood-brain-barrier permeability on drug
access have been studied by Ott et al. (1990) using PET and
Ga68-EDTA. This study has shown that there are rapid
changes in permeability at the site of primary cerebral lym-
phomas during chemotherapy. It appears likely that local
access of drugs to the tumour is radically impaired 4-5
weeks after treatment implying that drug treatment protocols
for cerebral tumours require careful planning.
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Cellular proliferation
Another area of growing interest in the applications of PET
to oncology is the possibility of measuring cell proliferation
rates in situ using F'8-fluorodeoxyuridine (FUDR) or C"-
thymidine (TDR). Wilson et al. (1990) have shown a strong
correlation between FUDR (an RNA label) uptake in glioma
and the histopathology of the tumour. In particular they
show that the growing edge of the tumour is well defined by
this agent. However the complex in vivo metabolism of this
agent has made it difficult to establish whether the localisa-
tion mechanisms is RNA labelling or due to amino acid
metabolites.
Two groups at Seattle, USA and Leuven, Belgium are
investigating the use of TDR. The former have shown
(Shields et al., 1990) that within 1 h of administration to the
dog 40-80% of the TDR is incorporated into DNA. Both
groups are presently working on methods of labelling TDR
in the ring-2 position as reported by Vander Borght et al.
(1990) to minimise the signal from metabolites. The images
will then give a more accurate measure of DNA incorpora-
tion.
Anti-cancer drug kinetics
The radiolabelling of anti-cancer drugs will enable measure-
ments of in vivo drug kinetics to be made using PET imaging.
Dimitrakopoulou et al. (1990a,b) have imaged tracer dose of
F'8-5FU given to patients with liver metastasis from colonic
carcinoma. These data show a strong correlation between the
initial uptake of the tracer in the metastases and the response
to 5FU therapy. Yang et al. (1990) have recently labelled
tamoxifen with F'8 and the group at ICR have labelled
iodo-tamoxifen with 1124 allowing the possibility of pre-
therapy tracer studies leading to dosimetry. It is also possible
of course to measure the uptake of radiolabelled drugs in
normal tissues which will allow a more accurate prediction of
toxicity to the kidneys, for instance, to therapy doses. With
the growing importance of systemic drug therapy such
methods of predicting drug uptake in individual patients are
likely to become of increasing value in managing limited
resources.
Receptor ligand imaging
The study of the role of PET receptor ligands in oncology is
still in its infancy, but initial reports indicate some success in
both localising tumours with appropriate ligands and in
determining receptor density from images. Muhr et al. (1986)
report the successful monitoring of the effects of bromocrip-
tine treatment on pituitary tumours using C"-N-methyl-
spiperone to visualise and quantify dopamine-D2 receptor
binding. Similar results were also obtained with C"I-raclo-
pride (Muhr et al., 1987).
Mintun et al. (1988) have developed several steroid recep-
tor ligands to quantify oestrogen and progestin receptors in
breast cancer. Using F'8-fluoroestradiol they show that the
uptake in primary breast masses as measured from PET
images correlates well with tumour oestrogen receptor con-
centration determined in vitro. They have also shown that
this tracer successfully localises involved nodes and distant
metastases and hence may be of value in assessing the likely
sensitivity of these sites to hormone therapy. The use of
steroid receptor ligands to monitor hormone therapy via PET
images is a real possibility and may be of particular value in
patients with widespread disease.
Tumour targeting
Tumour targeting with both protein and non-protein based
agents is of growing interest because of both the diagnostic
and therapeutic potential. PET imaging of such agents may
provide improved tumour localisation and dosimetry for
systemic therapy. Ott et al. (1987) and Flower et al. (1989)
have shown how imaging of I'24 in patients with hyper-
thyroidism and thyroid cancer can give both improved
images and allow accurate dosimetry to be carried out. In the
former case it has now been possible to produce a dose-
response relationship from the in vivo studies. Similar results
are now becoming available for the latter. This work, has
now been extended to the use of I124-metaiodobenzylguana-
dine (mIBG) in patients with neural crest tumours. Prelim-
inary data show that subtherapeutic radiation doses are likely
to be achieved in most cases in patients with pheochromo-
cytoma.
An obvious area of interest will be the use of positron
emitter labelled monoclonal antibodies to add improved sen-
sitivity and spatial resolution to the purported specificity of
these agents to tumours. Bakir et al. (1990) report successful
in vitro and laboratory based studies using I'24-labelled
ICR12, and c-erbB2 proto-oncogene product antibody which
may prove to be a useful prognostic tool in breast cancer.
Wilson et al. (1990) have quantitated the uptake of the
anti-EMA antibody HMFGI in both primary and locally
recurrent breast tumours again using 1124 as the tracer label.
They show that uptake in these tumours is generally only a
little larger than that obtained with a non-specific control
and found no correlation betw,en tumour uptake and blood
flow as measured using O'5-water.
A final interesting result comes from Seattle (Koh et al.,
1990) who have used the tracer F'8-fluoromisonidazole in an
attempt to determine the hypoxic fraction in tumours.
Preliminary studies in dog osteosarcomas have been extended
to patients with tumours of the head and neck. Positive
uptake of the tracer in excess of blood activity levels have
been seen, but the relationship of this result to the binding to
hypoxic cells has yet to be ascertained.
Conclusions
There are already some areas in which PET may have some
direct clinical input into oncology. The differentiation
between benign conditions such as radiation induced necrosis
and tumour regrowth is of obvious importance in a wide
range of tumour sites. Studies have shown that both F'8-
FDG and amino acids are appropriate tracers here. Measure-
ments of protein synthesis or cellular proliferation in vivo
should provide important methods for determining those
patients most likely to benefit from accelerated radiotherapy.
Similarily anti-cancer drugdopiihetry could well target expen-
sive treatment to responding patients and save non-respon-
ders from the worst of the side effects.
Whilst PET is still an expensive technique there will be five
centres in operation in the UK in the next 2 years and there
should be further possibilities to expand on a broader front
(Ott, 1987) by sharing radiopharmaceutical facilities on a
regional basis. The unique, quantitative, functional inform-
ation provided by PET makes it an exciting addition to the
imaging tools available to the oncologist to help improve
both diagnosis and therapy.POSITRON EMISSION TOMOGRAPHY AND ONCOLOGY 345
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